ReviewAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2018
State-of-the-Art Management of Germ Cell Tumors.
Review in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Extracranial, Extragonadal Germ Cell Tumors: A Multicenter Australian Case Series.Asia-Pacific journal of clinical oncology · 2026Observational
- Optimizing Diagnosis and Surgery for Pure Anterior Mediastinal Cysts: Insights from a Single-Centre Study.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- Intra-abdominal testicular teratoma complicated by torsion: A case report.Urology case reports · 2026Article
- Delayed Presentation of Mixed Testicular Tumor 19 Years After Orchiopexy: A Case Report and Literature Review.Research and reports in urology · 2025Article
- Nuclear medicine imaging in non-seminomatous germ cell tumors: lessons learned from the past failures.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses.European urology open science · 2024Article
- Active surveillance: minimising treatment while maximising outcomes in testis cancer.Translational andrology and urology · 2023Article
- Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.Gynecologic oncology · 2023Article
- Testicular cancer survivorship: Long-term toxicity and management.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Review
- Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372-3p, for Male Germ Cell Tumors, in a Clinical Laboratory Setting.The Journal of molecular diagnostics : JMD · 2022Article
- Mediastinal germ cell tumours: where we are and where we are going-a narrative review.Mediastinum (Hong Kong, China) · 2022Review
- Persistently elevated alpha-fetoprotein associated with chronic hepatitis B during chemotherapy for malignant ovarian germ cell tumors: a case series and a review of the literature.Journal of ovarian research · 2019Review
- Human germ cell tumours from a developmental perspective.Nature reviews. Cancer · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The state of the art management of germ cell tumors (GCT) in 2018 does not include novel agents targeting genomic alterations or exciting immunologic-based approaches but rather the avoidance of pitfalls in everyday practice. The relative rarity of GCT and high curability with correct management create the "perfect storm" for high-stakes errors to occur. This review focuses on several common pitfalls that should be avoided in staging and management of early-stage and advanced GCT in order to maximize patient outcomes. A particularly frequent misstep is to base treatment decisions on pre- rather than postorchiectomy tumor markers that, depending on marker directionality, can lead to either undertreatment with potentially inferior outcomes or overtreatment with excess toxicity. Another common mistake is the failure to consider the unique ability of GCT to differentiate and the distinct biology of teratoma (chemoresistance and lack of increased glucose uptake compared with normal tissue), which exerts a pervasive influence on nonseminoma management. This may lead to inappropriate use of PET scan to evaluate the postchemotherapy residual mass and, if negative, the conclusion that surgery is not needed whereas (FDG-negative) teratoma should be removed. It could also result in administration of additional unnecessary chemotherapy to patients with marker normalization but without robust radiographic response after 3 to 4 cycles of BEP. Finally, oncologists should strive to maintain standard chemotherapy doses, not substitute carboplatin for cisplatin, and refer to expert centers when expertise (e.g., RPLND) is not available locally in order to achieve optimal cure rates in advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.